JAK3-selective inhibitor peficitinib for the treatment of rheumatoid arthritis

References

• Firestein GS, McInnes IB. Immunopathogenesis of rheumatoid arthritis. Immunity. 2017;46(2):183–196.
   PubMed Web of Science ®Google Scholar
• Schwartz DM, Kanno Y, Villarino A, et al. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017;16(12):843–862.
   PubMed Web of Science ®Google Scholar
• Cañete JD, Hernández MV, Sanmartí R. Safety profile of biological therapies for treating rheumatoid arthritis. Expert Opin Biol Ther. 2017;17(9):1089–1103.
   PubMed Web of Science ®Google Scholar
• Atzeni F, Benucci M, Talotta R, et al. What are the dangers of biological therapy discontinuation or dose reduction strategies when treating rheumatoid arthritis? Expert Rev Clin Pharmacol. 2016;9(11):1403–1411.
   PubMed Web of Science ®Google Scholar
• Hamilton K, Clair EW. Tumour necrosis factor-alpha blockade: a new era for effective management of rheumatoid arthritis. Expert Opin Pharmacother. 2000;1(5):1041–1052.
   PubMedGoogle Scholar
• Aletaha D, Smolen JS. Diagnosis and management of rheumatoid arthritis: a review. Jama. 2018;320(13):1360–1372.
   PubMed Web of Science ®Google Scholar
• De Cock D, Van der Elst K, Meyfroidt S. The optimal combination therapy for the treatment of early rheumatoid arthritis. Expert Opin Pharmacother. 2015;16(11):1615–1625.
   PubMed Web of Science ®Google Scholar
• Luchetti MM, Benfaremo D, Gabrielli A. Biologics in inflammatory and immunomediated arthritis. Curr Pharm Biotechnol. 2017;18(12):989–1007.
   PubMed Web of Science ®Google Scholar
• Fleischmann RM, Iqbal I, Stern RL. Considerations with the use of biological therapy in the treatment of rheumatoid arthritis. Expert Opin Drug Saf. 2004;3(5):391–403.
   PubMedGoogle Scholar
• Levitzki A, Gazit A. Tyrosine kinase inhibition: an approach to drug development. Science. 1995;267(5205):1782–1788.
   PubMed Web of Science ®Google Scholar
• Jr RR. Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases. Pharmacol Res. 2016;111:784–803.
   PubMed Web of Science ®Google Scholar
• Thomis DC, Berg LJ. Peripheral expression of Jak3 is required to maintain T lymphocyte function. J Exp Med. 1997;185(2):197–206.
   PubMed Web of Science ®Google Scholar
• Nakamura K, Inami M, Morio H, et al. AS2553627, a novel JAK inhibitor, prevents chronic rejection in rat cardiac allografts. Eur J Pharmacol. 2017;796:69–75.
   PubMed Web of Science ®Google Scholar
• Nakajima Y, Inoue T, Nakai K, et al. Synthesis and evaluation of novel 1H-pyrrolo[2,3-b]pyridine-5-carboxamide derivatives as potent and orally efficacious immunomodulators targeting JAK3. Bioorg Med Chem. 2015;23(15):4871–4883.
   PubMed Web of Science ®Google Scholar
• Flanagan ME, Blumenkopf TA, Brissette WH, et al. Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection. J Med Chem. 2010;53(24):8468–8484.
   PubMed Web of Science ®Google Scholar
• Fleischmann R. A review of tofacitinib efficacy in rheumatoid arthritis patients who have had an inadequate response or intolerance to methotrexate. Expert Opin Pharmacother. 2017;18(14):1525–1533.
   PubMed Web of Science ®Google Scholar
• Thoma G, Drückes P, Zerwes HG. Selective inhibitors of the Janus kinase Jak3–are they effective? Bioorg Med Chem Lett. 2014;24(19):4617–4621.
   PubMed Web of Science ®Google Scholar
• Smith GA, Uchida K, Weiss A, et al. Essential biphasic role for JAK3 catalytic activity in IL-2 receptor signaling. Nat Chem Biol. 2016;12(5):373–379.
   PubMed Web of Science ®Google Scholar
• Vély F, Barlogis V, Vallentin B, et al. Evidence of innate lymphoid cell redundancy in humans. Nat Immunol. 2016;17(11):1291–1299.
   PubMed Web of Science ®Google Scholar
• Krause A, Scaletta N, Ji JD, et al. Rheumatoid arthritis synoviocyte survival is dependent on Stat3. J Immunol. 2002;169(11):6610–6616.
   PubMed Web of Science ®Google Scholar
• Kim SK, Park KY, Yoon WC, et al. Melittin enhances apoptosis through suppression of IL-6/sIL-6R complex-induced NF-κB and STAT3 activation and Bcl-2 expression for human fibroblast-like synoviocytes in rheumatoid arthritis. Joint Bone Spine. 2011;78(5):471–477.
   PubMed Web of Science ®Google Scholar
• Wang F, Sengupta TK, Zhong Z, et al. Regulation of the balance of cytokine production and the signal transducer and activator of transcription (STAT) transcription factor activity by cytokines and inflammatory synovial fluids. J Exp Med. 1995;182(6):1825–1831.
   PubMed Web of Science ®Google Scholar
• Walker JG, Ahern MJ, Coleman M, et al. Changes in synovial tissue Jak-STAT expression in rheumatoid arthritis in response to successful DMARD treatment. Ann Rheum Dis. 2006;65(12):1558–1564.
   PubMed Web of Science ®Google Scholar
• Carrión M, Juarranz Y, Martínez C, et al. IL-22/IL-22R1 axis and S100A8/A9 alarmins in human osteoarthritic and rheumatoid arthritis synovial fibroblasts. Rheumatology (Oxford). 2013;52(12):2177–2186.
   PubMed Web of Science ®Google Scholar
• Cornejo MG, Kharas MG, Werneck MB, et al. Constitutive JAK3 activation induces lymphoproliferative syndromes in murine bone marrow transplantation models. Blood. 2009;113(12):2746–2754.
   PubMed Web of Science ®Google Scholar
• Chen M, Cheng A, Candotti F, et al. Complex effects of naturally occurring mutations in the JAK3 pseudokinase domain: evidence for interactions between the kinase and pseudokinase domains. Mol Cell Biol. 2000;20(3):947–956.
   PubMed Web of Science ®Google Scholar
• Candotti F, Oakes SA, Johnston JA, et al. Structural and functional basis for JAK3-deficient severe combined immunodeficiency. Blood. 1997;90(10):3996–4003.
   PubMed Web of Science ®Google Scholar
• Zhou YJ, Chen M, Cusack NA, et al. Unexpected effects of FERM domain mutations on catalytic activity of Jak3: structural implication for Janus kinases. Mol Cell. 2001;8(5):959–969.
   PubMed Web of Science ®Google Scholar
• Alghasham A, Rasheed Z. Therapeutic targets for rheumatoid arthritis: progress and promises. Autoimmunity. 2014;47(2):77–94.
   PubMed Web of Science ®Google Scholar
• Villarino AV, Kanno Y, Ferdinand JR, et al. Mechanisms of Jak/STAT signaling in immunity and disease. J Immunol. 2015;194(1):21–27.
   PubMed Web of Science ®Google Scholar
• Li HS, Watowich SS. Innate immune regulation by STAT-mediated transcriptional mechanisms. Immunol Rev. 2014;261(1):84–101.
   PubMed Web of Science ®Google Scholar
• Riese RJ, Krishnaswami S, Kremer J. Inhibition of JAK kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomes. Best Pract Res Clin Rheumatol. 2010;24(4):513–526.
   PubMed Web of Science ®Google Scholar
• Williams NS, Klem J, Puzanov IJ, et al. Natural killer cell differentiation: insights from knockout and transgenic mouse models and in vitro systems. Immunol Rev. 1998;165:47–61.
   PubMed Web of Science ®Google Scholar
• Magyari L, Varszegi D, Kovesdi E, et al. Interleukins and interleukin receptors in rheumatoid arthritis: research, diagnostics and clinical implications. World J Orthop. 2014;5(4):516–536.
   PubMedGoogle Scholar
• Alves de Medeiros AK, Speeckaert R, Van Gele M, et al. JAK3 as an emerging target for topical treatment of inflammatory skin diseases. Plos One. 2016;11(10):e0164080.
   PubMed Web of Science ®Google Scholar
• West K. CP-690550, a JAK3 inhibitor as an immunosuppressant for the treatment of rheumatoid arthritis, transplant rejection, psoriasis and other immune-mediated disorders. Curr Opin Invest Drugs. 2009;10(5):491–504.
   PubMed Web of Science ®Google Scholar
• Norman P. Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin Investig Drugs. 2014;23(8):1067–1077.
   PubMed Web of Science ®Google Scholar
• Lam S. JAK inhibitors: A broadening approach in rheumatoid arthritis. Drugs Today (Barc). 2016;52(8):467–469.
   PubMed Web of Science ®Google Scholar
• Hamaguchi H, Amano Y, Moritomo A, et al. Discovery and structural characterization of peficitinib (ASP015K) as a novel and potent JAK inhibitor. Bioorg Med Chem. 2018;26(18):4971–4983.
   PubMed Web of Science ®Google Scholar
• Gu L, Zhuang H, Safina B, et al. Combinatorial approach to identification of tyrphostin inhibitors of cytokine signaling. Bioorg Med Chem. 2005;13(13):4269–4278.
   PubMed Web of Science ®Google Scholar
• Ito M, Yamazaki S, Yamagami K, et al. A novel JAK inhibitor, peficitinib, demonstrates potent efficacy in a rat adjuvant-induced arthritis model. J Pharmacol Sci. 2017;133(1):25–33.
   PubMed Web of Science ®Google Scholar
• Cao YJ, Sawamoto T, Valluri U, et al. Pharmacokinetics, pharmacodynamics, and safety of ASP015K (Peficitinib), a new Janus Kinase inhibitor, in healthy subjects. Clin Pharmacol Drug Dev. 2016;5(6):435–449.
   PubMed Web of Science ®Google Scholar
• Sands BE, Sandborn WJ, Feagan BG, et al. Peficitinib, an oral Janus Kinase inhibitor, in moderate-to-severe ulcerative colitis: results from a randomised, phase 2 study. J Crohns Colitis. 2018;12(10):1158–1169.
   PubMed Web of Science ®Google Scholar
• McCormick JW, Vogel PD, Wise JG. Multiple drug transport pathways through human P-glycoprotein. Biochemistry. 2015;54(28):4374–4390.
   PubMed Web of Science ®Google Scholar
• Lin JH, Yamazaki M. Role of P-glycoprotein in pharmacokinetics. Clin Pharmacokinet. 2003;41(1):59–98.
   Google Scholar
• Zhu T, Howieson C, Wojtkowski T, et al. The effect of verapamil, a P-glycoprotein inhibitor, on the pharmacokinetics of peficitinib, an orally administered, once-daily JAK inhibitor. Clin Pharmacol Drug Dev. 2017;6(6):548–555.
   PubMed Web of Science ®Google Scholar
• Niemi M, Pasanen MK, Neuvonen PJ. Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011;63(1):157–181.
   PubMed Web of Science ®Google Scholar
• Allred AJ, Bowen CJ, Park JW, et al. Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers. Br J Clin Pharmacol. 2011;72(2):321–329.
   PubMed Web of Science ®Google Scholar
• Takeuchi T, Tanaka Y, Iwasaki M, et al. Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study. Ann Rheum Dis. 2016;75(6):1057–1064.
   PubMed Web of Science ®Google Scholar
• Genovese MC, Greenwald M, Codding C, et al. Peficitinib, a JAK Inhibitor, in combination with limited conventional synthetic disease-modifying antirheumatic drugs in the treatment of moderate-to-severe rheumatoid arthritis. Arthritis Rheumatol. 2017;69(5):932–942.
   PubMed Web of Science ®Google Scholar
• Kivitz AJ, Gutierrez-Ureña SR, Poiley J, et al. Peficitinib, a JAK Inhibitor, in the treatment of moderate-to-severe rheumatoid arthritis in patients with an inadequate response to methotrexate. Arthritis Rheumatol. 2017;69(4):709–719.
   PubMed Web of Science ®Google Scholar
• Pfizer. Disclosed document for new drug application of XELJANZ ® (tofacitinib); 2015.
   Google Scholar
• Fleischmann R, Kremer J, Cush J, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012;367:495–507.
   PubMed Web of Science ®Google Scholar
• Martin P, Gillen M, Millson D, et al. Effects of fostamatinib on the pharmacokinetics of digoxin (a P-glycoprotein substrate): results from in vitro and phase I clinical studies. Clin Ther. 2015;37:2811–2822.
   PubMed Web of Science ®Google Scholar
• Shumaker RC, Aluri J, Fan J, et al. Effect of rifampicin on the pharmacokinetics of lenvatinib in healthy adults. Clin Drug Investig. 2014;34(9):651–659.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Rheumatoid arthritis; 2012 [cited 2019 Jan 8]. Available from: http://www.cdc.gov/arthritis/basics/rheumatoid.htm.
   Google Scholar
• Smolen JS, Aletaha D, Bijlsma JWJ, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010;69(4):631–637.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence. Quick reference guide rheumatoid arthritis: the management of rheumatoid arthritis in adults (NICE clinical guideline 79); 2009 [cited 2019 Jan 8]. Available from: http://www.nice.org.uk/nicemedia/live/12131/43329/43329.pdf
   Google Scholar
• Wilkie WS, Schwieterman P. Strategies for the management of rheumatoid arthritis. Orthopedics. 2012;35(2):125–130.
   PubMed Web of Science ®Google Scholar
• Menet CJ, Rompaey LV, Geney R. Advances in the discovery of selective JAK inhibitors. Prog Med Chem. 2013;52:153–223.
   PubMedGoogle Scholar
• Papp K, Pariser D, Catlin M, et al. A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate-to-severe psoriasis. Br J Dermatol. 2015;173(3):767–776.
   PubMed Web of Science ®Google Scholar
• Strober W, Fuss IJ. Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases. Gastroenterology. 2011;140:1756–1767.
   PubMed Web of Science ®Google Scholar